Thrombosis Research
Volume 121, Issue 2 , Pages 183-191, 2007

A segment of Staphylococcus aureus clumping factor A with fibrinogen-binding activity (ClfA221–550) inhibits platelet-plug formation in mice

  • Chao-Zong Liu

      Affiliations

    • Department of Pharmacology, College of Medicine, Tzu Chi University, 701, Chung-Yang Road, Sec. 3, Hualien 970, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886 3 856 5301x7511; fax: +886 3 856 1465.
  • ,
  • Tur-Fu Huang

      Affiliations

    • Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan
  • ,
  • Po-Jun Tsai

      Affiliations

    • Department of Pharmacy, Dalin Tzu Chi Buddhist General Hospital, Dalin, Chia-Yi County, Taiwan
  • ,
  • Pei-Jane Tsai

      Affiliations

    • Department of Laboratory Medicine and Biotechnology, College of Medicine, Tzu Chi University, Hualien, Taiwan
  • ,
  • Ling-Ya Chang

      Affiliations

    • Department of Pharmacology, College of Medicine, Tzu Chi University, 701, Chung-Yang Road, Sec. 3, Hualien 970, Taiwan
  • ,
  • Mei-Chi Chang

      Affiliations

    • Biomedical Science Team, Chen Kang College of Technology, Kwei Shan, Tao-Yuan County, Taiwan

Received 21 November 2006; received in revised form 1 March 2007; accepted 22 March 2007.

Abstract 

We previously reported that the fibrinogen-binding segment (residues 221–550) of Staphylococcus aureus clumping factor A (ClfA), which binds to fibrinogen γ chain C-terminus, exerted inhibitory effects on platelet aggregation and fibrin clot formation in vitro. Here, we further demonstrated the effectiveness of using ClfA221–550 to inhibit platelet-rich thrombus formation in vivo. Platelet-rich thrombi were formed in the mesenteric venules of fluorescein-loaded mice by filtered light illumination. It grew rapidly and ultimately resulted in the cessation of blood flow due to vessel occlusion. Given by intravenous bolus injection, ClfA221–550 delayed occlusive thrombi formation in a dose-dependent manner: 2-, 3- and 4.5-fold prolongations of vessel occlusion time were attained with 0.69, 6.9 and 34.5 mg/kg of ClfA221–550, respectively. Reduced fibrin clot formation at the late phase with plasmas, which were prepared from ClfA221–550-treated mice, was also dose-dependent. The suppression of fibrin formation ex vivo coincided with the delay of occlusive thrombus formation in vivo, suggesting that the antithrombotic effect of ClfA221–550 may result from the blockade of fibrinogen γ chain C-terminal functions, in mediating platelet aggregation and fibrin clot formation. Administration of ClfA221–550 also lengthened the tail bleeding of mice; however, significant effect was achieved only with a higher dosage, namely 34.5 mg/kg. These results together showed that blockade of fibrinogen γ chain C-terminus with ClfA221–550 preferentially affected platelet-rich thrombus formation rather than normal haemostasis, thus providing a rationale for selecting fibrinogen γ chain C-terminus as a new target for thrombotic intervention.

Abbreviations: ClfA, clumping factor A, GP, glycoprotein, GST, glutathione S-transferase, TBS, Tris-buffered saline, SDS-PAGE, sodium dodecylsulfate-polyacrylamide gel electrophoresis, aPTT, activated partial thromboplastin time, PT, prothrombin time

Keywords: Antithrombotic, Fibrinogen γ chain C-terminus, Platelet, Clumping factor A, Fibrinogen binding protein

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0049-3848(07)00119-3

doi:10.1016/j.thromres.2007.03.019

Thrombosis Research
Volume 121, Issue 2 , Pages 183-191, 2007